F13B — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL21510939	1.00	1/20
SCHEMBL21510937	0.96	1/20
SCHEMBL21510595	0.91	1/20
SCHEMBL21510629	0.90	1/20
SCHEMBL21510597	0.90	1/20
SCHEMBL21514830	0.90	1/20
SCHEMBL21514973	0.90	1/20
SCHEMBL21510601	0.88	1/20
SCHEMBL23371665	0.87	1/20
SCHEMBL21510600	0.87	1/20
SCHEMBL23371674	0.86	1/20
SCHEMBL21510596	0.86	1/20
SCHEMBL21510943	0.86	1/20
SCHEMBL21514972	0.86	1/20
SCHEMBL21510667	0.86	1/20
SCHEMBL21510593	0.83	1/20
SCHEMBL21514853	0.83	1/20
SCHEMBL21494536	0.82	1/20
SCHEMBL21494537	0.82	1/20
SCHEMBL21486560	0.80	1/20

Clinical trials — most relevant to F13B by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
PCC Treatment for Hemophilia Patients With Inhibitor（2022PCC-A）	PHASE4	RECRUITING
Levonorgestrel-releasing Intrauterine System in Patients With Endometriosis	PHASE4	COMPLETED
Efficacy and Cost Effectiveness of Pharmacokinetic Dosing in Haemophilia A	PHASE4	COMPLETED
An Open Label Study to Determine the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia A.	PHASE3	COMPLETED
Phase III Expansion Trial for Determining the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia A	PHASE3	COMPLETED
Effect of Hyperglycemia in PAI-1 Activity and the Relationship With Outcome in Severe Sepsis and Septic Shock	PHASE2/PHASE3	COMPLETED
Gemcitabine With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer	PHASE3	COMPLETED
Open-Label Single Ascending Dose of Adeno-associated Virus Serotype 8 Factor IX Gene Therapy in Adults With Hemophilia B	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING
Effects of TNX-832 (Sunol cH36) in Subjects With Acute Lung Injury/Acute Respiratory Distress Syndrome	PHASE1	COMPLETED
Safety and Dosing Evaluation of REG1 Anticoagulation System	PHASE1	COMPLETED
Correlation Between PT and INR to Factor 7	nan	UNKNOWN
Hypolipemic Treatment in Acute Coronary Syndrome (ACS): Antithrombotic Effects	nan	UNKNOWN
Cross-sectional Study on Prevalence of Coagulation Factors Deficiency in Assiut University Children Hospital	nan	UNKNOWN
Hormone Replacement Therapy and Prothrombotic Variants	nan	COMPLETED
Heparin Management During Cardiopulmonary Bypass in Children	nan	COMPLETED
Risk Markers in the Acute Coronary Syndromes	nan	COMPLETED
Treatment of Congenital Factor VII Deficiency	nan	COMPLETED
Coagulation After Intravenous Methylprednisolone Administration	nan	COMPLETED
Individualized Multimodal Hemostasis Evaluation Pyramid (IMHOTEP)	nan	COMPLETED
The Lived Experience of People With Von Willebrand Disease	nan	COMPLETED
Factor XIII Activity in Gastrointestinal Bleedings	nan	COMPLETED
In-vivo Thrombus Imaging With 18F-GP1, a Novel Platelet PET Radiotracer	nan	COMPLETED
Real-life Clinical FEIBA Samples Measured Using the Version A of the HemA EnzySystem	nan	COMPLETED
Effect of Bevacizumab and VEGF on Platelet Clustering in Patients Who Are Receiving Bevacizumab for Cancer	nan	UNKNOWN
The Change of Coagulation Markers in Children With β-thalassemia Disease After Stem Cell Transplantation	nan	COMPLETED
Common Variants in Candidate Genes and Premature MI Risk	nan	COMPLETED
The Role of Platelet Surface α2β1 Integrin Expression as a Risk Factor in Thrombotic and/or Bleeding Complications	nan	COMPLETED
Estimation of Coagulation Factor XIII Activity Based on the Initial Plasma Fibrinogen Level in Trauma	nan	COMPLETED
Hemostasis in Sickle Cell Disease--Infancy to Adulthood	nan	COMPLETED
Prevention of Bleeding in Patients With Moderate and Severe Hemophilia A Playing Sports: A Comparison Between Factor VIII and Emicizumab Prophylaxis	nan	RECRUITING

Related proteins — ESM-2 sequence neighbours (a F13B binder may also engage these)

Protein	Name	Similarity
Q07968	—	0.997	Q07968 →
O08569	—	0.988	O08569 →
P04003	—	0.988	P04003 →
Q60736	—	0.987	Q60736 →
P08607	—	0.987	P08607 →
Q63514	—	0.984	Q63514 →
Q28065	—	0.983	Q28065 →
Q95LB0	—	0.982	Q95LB0 →
P02749	—	0.982	P02749 →
P17690	—	0.981	P17690 →
Q7TSY4	—	0.981	Q7TSY4 →
Q22328	—	0.981	Q22328 →
P26644	—	0.980	P26644 →
P33703	—	0.980	P33703 →
Q9Z0M4	—	0.979	Q9Z0M4 →
O88174	—	0.979	O88174 →
P68639	—	0.979	P68639 →
P68638	—	0.979	P68638 →
Q03472	—	0.978	Q03472 →
Q01339	—	0.978	Q01339 →
P20023	—	0.976	P20023 →
P19070	—	0.975	P19070 →
Q8HYX8	—	0.974	Q8HYX8 →
P98105	—	0.972	P98105 →
P27113	—	0.971	P27113 →
Q63135	—	0.971	Q63135 →
P20851	—	0.971	P20851 →
P98107	—	0.970	P98107 →
SELE	E-selectin	0.970	landscape →
Q61476	—	0.970	Q61476 →